[The role of psychopharmacotherapy in combined treatment of patients with metabolic syndrome and depression].
To evaluate efficacy and tolerance of combined treatment with antidepressant cipramil in patients with metabolic syndrome (MS). We examined 23 MS patients with depression (mean age 47 +/- 7.4 years). For diagnosis and somatic state evaluation we used clinical, device and laboratory tests. The clinicopsychopathological method, MADRS and CGI scales were applied for assessment of mental state and treatment efficacy. We achieved positive effects of 12-week combined somatotropic and psychotropic therapy on carbohydrate metabolism: a significant decrease of fasting blood glucose from 6.6 +/- 1.4 to 6.2 +/- 0.7 mmol and postprandial (2 hours after meal) glucose from 8.6 +/- 1.5 to 7.8 +/- 0.8 mmol/l, of waist circumference from 106.0 +/- 11.93 to 103.5 +/- 12.3 cm, body mass index from 32.5 +/- 4.54 to 31.4 +/- 4.76 kg m2, systolic blood pressure from 154.52 +/- 7.4 to 137.91 +/- 13.8 mm Hg and diastolic blood pressure from 90.1 +/- 6.2 to 81.0 +/- 6.6 mm Hg. A significant change in the levels of total cholesterol and triglycerides was not registered. Administration of antidepressant in MS patients relieved depression. This improved carbohydrate metabolism, lowered blood pressure and body mass index.